Obesity trials recruiting in Kentucky

All Obesity trials nationally

Cities in Kentucky

Recruiting trials in Kentucky

• 2024 Tirzepatide-Bariatric Surgery
  NCT06721507 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Lexington
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Louisville
• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
  NCT06143956 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Kentucky: Louisville
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Louisville
• A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
  NCT07656727 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Lexington
• A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.
  NCT07570758 · Phase: Phase 2 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Kentucky: Louisville
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Kentucky: Louisville
• A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
  NCT07639021 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Louisville
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Lexington
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Lexington, Louisville, Owensboro
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Lexington
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
  NCT07142707 · Phase: Phase 1 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Kentucky: Lexington
• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
  NCT07589608 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Kentucky: Louisville
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
  NCT06857942 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Bowling Green
• A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
  NCT07595549 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Louisville
• A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
  NCT07477704 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Kentucky: Louisville
• A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
  NCT07662122 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Kentucky: Louisville
• AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07509307 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Louisville
• Adrenergic Cholinergic Enteric Measures/Mapping
  NCT04013282 · Phase: Not specified · Ages: 10 Years to 80 Years · Sex: All (male and female) · Kentucky: Louisville
• Cannabis for Obesity Trial
  NCT06137365 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Kentucky: Lexington
• Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
  NCT07654361 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Kentucky: Louisville
• Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
  NCT07353931 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Louisville
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
  NCT07037433 · Phase: Phase 3 · Ages: 45 Years to 99 Years · Sex: All (male and female) · Kentucky: Louisville
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
  NCT07684235 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Kentucky: Louisville
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Kentucky: Lexington
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
  NCT06937086 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Kentucky: Louisville
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
  NCT06937099 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Kentucky: Louisville
• Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
  NCT06967389 · Phase: Not specified · Ages: 12 Years to 17 Years · Sex: All (male and female) · Kentucky: Lexington
• Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
  NCT07770841 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Louisville
• Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
  NCT07752979 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Kentucky: Louisville
• Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
  NCT07685808 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Kentucky: Lexington
• The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
  NCT05051436 · Phase: Phase 4 · Ages: 35 Years to 65 Years · Sex: All (male and female) · Kentucky: Lexington